Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SPECC1L-ADORA2A readthrough is a naturally occurring non-coding RNA transcript generated by readthrough transcription between the adjacent SPECC1L and ADORA2A genes on chromosome 22. This chimeric transcript is a candidate for nonsense-mediated decay and is not believed to produce any functional protein. There are no known biological functions, disease roles, or pharmacological targets associated with the SPECC1L-ADORA2A transcript itself. It is not considered a therapeutic target or a receptor, enzyme, transporter, or other protein product[1][3].\n\n**Note**: The individual genes involved in the readthrough—**SPECC1L** (a cytoskeletal protein involved in cell adhesion and migration) and **ADORA2A** (a G protein–coupled adenosine receptor gene)—have biological significance. However, this specific readthrough does not encode a functional molecule and is not a therapeutic target[1][3].\n\n**Summary of error**: SPECC1L-ADORA2A is not a canonical protein target but instead a non-coding readthrough transcript, so should not be annotated as a therapeutic or functional biomolecular target[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPECC1L-ADORA2A readthrough transcript (SPECC1L-ADORA2A).